ImmunoPrecise, Mila partner on antibody therapeutics

By The Science Advisory Board staff writers

November 3, 2020 -- ImmunoPrecise Antibodies and artificial intelligence (AI) research institute Mila have formed a partnership to collaborate on research and talent development initiatives for antibody-based therapeutics.

Specifically, the partnership will apply AI to unexplored datasets generated by ImmunoPrecise's therapeutic antibody discovery platforms to help the design of new therapeutics against life-threatening diseases, according to the companies.

If you like this content, please share it with a colleague!

Related Reading

ImmunoPrecise, Twist collaborate on novel therapeutics
ImmunoPrecise subsidiary Talem Therapeutics and Twist Bioscience will collaborate on the creation of novel therapeutic molecules.

ImmunoPrecise, LiteVax begin preclinical studies of SARS-CoV-2 vaccine
ImmunoPrecise and LiteVax have commenced preclinical SARS-CoV-2 vaccine trials.

ImmunoPrecise subsidiary expands B cell Select platform
IPA Europe, a subsidiary of ImmunoPrecise Antibodies, has expanded its foundational B cell Select platform for seamless integration into ImmunoPrecise's...

ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody
ImmunoPrecise and Zymeworks announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.

Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit...